81256-89-5

Usage

Uses

Used in Oligonucleotide Synthesis:
N2-isobutyryl-5'-O-(4,4'-dimethoxytrityl)-3'-O-tert-butyldimethylsilyl guanosine is used as a building block in the synthesis of oligonucleotides, particularly for the preparation of modified nucleic acid analogs. Its specific structural modifications allow for enhanced stability and functionality in nucleic acid-based technologies.
Used in Research and Medical Applications:
N2-isobutyryl-5'-O-(4,4'-dimethoxytrityl)-3'-O-tert-butyldimethylsilyl guanosine is utilized in research and medical applications for the development of modified nucleic acid analogs. Its protective groups facilitate the synthesis of complex oligonucleotide structures, which can be used for various purposes, such as targeted drug delivery, molecular diagnostics, and therapeutic interventions.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, N2-isobutyryl-5'-O-(4,4'-dimethoxytrityl)-3'-O-tert-butyldimethylsilyl guanosine is used as a key intermediate in the synthesis of nucleic acid-based drugs. Its protective groups ensure the successful synthesis of complex drug candidates with improved pharmacological properties.
Used in Biotechnology Industry:
In the biotechnology industry, N2-isobutyryl-5'-O-(4,4'-dimethoxytrityl)-3'-O-tert-butyldimethylsilyl guanosine is employed in the development of nucleic acid-based tools and technologies, such as gene editing, gene regulation, and molecular detection systems. Its protective groups enable the synthesis of highly specific and stable nucleic acid constructs for various biotechnological applications.

Upstream product

• 18162-48-6 tert-butyldimethylsilyl chloride 
• 81246-83-5 9-(5-O-dimethoxytrityl-β-D-ribofuranosyl)-2-N-isobutyrylguanine 
• 64350-24-9 N²-isobutyryl-2'-deoxyguanosine 
• 118-00-3 G 

Downstream Products

• 201667-38-1 N-{9-[(2R,3R,4R,5R)-5-[Bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-4-(tert-butyl-dimethyl-silanyloxy)-3-methylsulfanylmethoxy-tetrahydro-furan-2-yl]-6-oxo-6,9-dihydro-1H-purin-2-yl}-isobutyramide 
• 1187644-22-9 N₂-isobutyryl-5'-O-(4,4'-dimethoxytrityl)-3'-O-tertbutyldimethylsilyl-2'-sulfamoyl-guanosine 
• 1187644-14-9 N₂-isobutyryl-5'-O-(4,4'-dimethoxytrityl)-3'-O-tertbutyldimethylsilyl-2'-O-(2-cyanoethyl)-phosphonate guanosine 
• 201667-44-9 N-(9-{(2R,3R,4R,5R)-5-[Bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-4-hydroxy-3-methylsulfanylmethoxy-tetrahydro-furan-2-yl}-6-oxo-6,9-dihydro-1H-purin-2-yl)-isobutyramide 

Relevant academic research and scientific papers

CYCLIC DINUCLEOTIDES AS STING AGONISTS

Disclosed are compounds, compositions and methods for treating of diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein R, R1B, R1C, R2B

COMPOUNDS FOR TREATING BACTERIAL INFECTIONS

The present invention relates to a novel class of guanine nucleotide analogs which inhibit RelA and Relseq synthetic activity and which possess anti-bacterial activity. The present invention also relates to pharmaceutical compositions that include such compounds, and to methods of use of such compounds or compositions for combating bacteria and treating bacterial infections.

ppGpp analogues inhibit synthetase activity of Rel proteins from Gram-negative and Gram-positive bacteria

A prominent feature of the stringent response is the accumulation of two unusual phosphorylated derivatives of GTP and GDP (pppGpp: 5′-triphosphate-3′-diphosphate, and ppGpp: 5′-3′-bis-diphosphate), collectively called (p)ppGpp, within a few seconds after the onset of amino-acid starvation. The synthesis of these 'alarmone' compounds is catalyzed by RelA homologues. Other features of the stringent response include inhibition of stable RNA synthesis and modulation of transcription, replication, and translation. (p)ppGpp accumulation is important for virulence induction, differentiation and antibiotic resistance. We have synthesized a group of (p)ppGpp analogues and tested them as competitive inhibitors of Rel proteins in vitro. 2′-Deoxyguanosine-3′-5′-di(methylene bisphosphonate) [compound (10)] was found as an inhibitor that reduces ppGpp formation in both Gram-negative and Gram-positive bacteria. In silico docking together with competitive inhibition analysis suggests that compound (10) inhibits activity of Rel proteins by competing with GTP/GDP for its binding site. As Rel proteins are completely absent in mammalians, this appears to be a very attractive approach for the development of novel antibacterial agents.

Modified phosphotriester method for chemical synthesis of ribooligonucleotides. Part I. Synthesis of riboundecaadenylate and two fragments constituting the sequence of R-17 translation control signal

A modified phosphotriester method has been succesfully applied for the chemical synthesis of ribooligonucleotides.The starting material is a fully protected ribomononucleoside containing a 3'-phosphotriester group 5.The coupling reaction is performed usin